During the last session, Acrivon Therapeutics Inc (NASDAQ:ACRV)’s traded shares were 1.85 million, with the beta value of the company hitting 0.80. At the end of the trading day, the stock’s price was $2.61, reflecting an intraday loss of -51.58% or -$2.78. The 52-week high for the ACRV share is $11.90, that puts it down -355.94 from that peak though still a striking -79.69% loss since the share price plummeted to a 52-week low of $4.69. The company’s market capitalization is $81.26M, and the average intraday trading volume over the past 10 days was 26810.0 shares, and the average trade volume was 48.77K shares over the past three months.
Acrivon Therapeutics Inc (ACRV) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ACRV has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.7.
Acrivon Therapeutics Inc (NASDAQ:ACRV) trade information
Acrivon Therapeutics Inc (ACRV) registered a -51.58% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -51.58% in intraday trading to $2.61, hitting a weekly high. The stock’s 5-day price performance is -52.20%, and it has moved by -52.80% in 30 days. Based on these gigs, the overall price performance for the year is -57.84%. The short interest in Acrivon Therapeutics Inc (NASDAQ:ACRV) is 0.73 million shares and it means that shorts have 19.11 day(s) to cover.
The consensus price target of analysts on Wall Street is $27, which implies an increase of 90.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $27 and $27 respectively. As a result, ACRV is trading at a discount of -934.48% off the target high and -934.48% off the low.
While earnings are projected to return 5.95% in 2025, the next five years will return -1.53% per annum.
ACRV Dividends
Acrivon Therapeutics Inc is due to release its next quarterly earnings on 2024-Nov-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Acrivon Therapeutics Inc (NASDAQ:ACRV)’s Major holders
Acrivon Therapeutics Inc insiders own 22.06% of total outstanding shares while institutional holders control 74.98%, with the float percentage being 96.20%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 92.0 institutions own stock in it. As of 2024-06-30, the company held over 8.34 million shares (or 23.083% of all shares), a total value of $48.37 million in shares.
The next largest institutional holding, with 5.36 million shares, is of PERCEPTIVE ADVISORS LLC’s that is approximately 14.8366% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $31.09 million.
Also, the Mutual Funds coming in first place with the largest holdings of Acrivon Therapeutics Inc (ACRV) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Dec 31, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 407.49 shares. This amounts to just over 1.31 percent of the company’s overall shares, with a $1.06 million market value. The same data shows that the other fund manager holds slightly less at 297.75, or about 0.96% of the stock, which is worth about $0.78 million.
